Literature DB >> 9627938

Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers.

B W McBride1, A Mogg, J L Telfer, M S Lever, J Miller, P C Turnbull, L Baillie.   

Abstract

The efficacy of recombinant Bacillus anthracis Protective Antigen (rPA) produced in Bacillus subtilis and formulated in Alhydrogel or MPL-TDM-CWS (Ribi adjuvant) has been tested and compared to the licensed UK human vaccine in guinea pigs challenged by the aerosol route with the Ames strain of B. anthracis. rPA combined with the Ribi adjuvant was found to be the only formulation to provide 100% protection from challenge. Analysis of immunological parameters in the individual animals revealed significant differences between the rPA/Ribi vaccine group and rPA/Alhydrogel and human vaccine groups for antigen specific lymphocyte proliferation, PA neutralisation and antigen specific IgG2 levels, but indicated no significant differences in PA-specific IgG1 levels. rPA formulated in Alhydrogel induced a mainly IgG1 response whilst the rPA/Ribi vaccine produced a predominantly IgG2 response.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9627938     DOI： 10.1016/s0264-410x(97)00268-5

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  32 in total

1.  Search for correlates of protective immunity conferred by anthrax vaccine.

Authors:  S Reuveny; M D White; Y Y Adar; Y Kafri; Z Altboum; Y Gozes; D Kobiler; A Shafferman; B Velan
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

2.  Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax.

Authors:  E D Williamson; I Hodgson; N J Walker; A W Topping; M G Duchars; J M Mott; J Estep; C Lebutt; H C Flick-Smith; H E Jones; H Li; C P Quinn
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

3.  Cationic liposomes containing mycobacterial lipids: a new powerful Th1 adjuvant system.

Authors:  Ida Rosenkrands; Else Marie Agger; Anja W Olsen; Karen S Korsholm; Claire Swetman Andersen; Klaus T Jensen; Peter Andersen
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

4.  Plant-based vaccine: mice immunized with chloroplast-derived anthrax protective antigen survive anthrax lethal toxin challenge.

Authors:  Vijay Koya; Mahtab Moayeri; Stephen H Leppla; Henry Daniell
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

5.  Direct inhibition of T-lymphocyte activation by anthrax toxins in vivo.

Authors:  Jason E Comer; Ashok K Chopra; Johnny W Peterson; Rolf König
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

Review 6.  Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines.

Authors:  Andrew J Phipps; Christopher Premanandan; Roy E Barnewall; Michael D Lairmore
Journal:  Microbiol Mol Biol Rev       Date:  2004-12       Impact factor: 11.056

7.  A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques.

Authors:  Conrad P Quinn; Carol L Sabourin; Nancy A Niemuth; Han Li; Vera A Semenova; Thomas L Rudge; Heather J Mayfield; Jarad Schiffer; Robert S Mittler; Chris C Ibegbu; Jens Wrammert; Rafi Ahmed; April M Brys; Robert E Hunt; Denyse Levesque; James E Estep; Roy E Barnewall; David M Robinson; Brian D Plikaytis; Nina Marano
Journal:  Clin Vaccine Immunol       Date:  2012-08-29

8.  Domain specificity of the human antibody response to Bacillus anthracis protective antigen.

Authors:  Donald C Reason; Anuska Ullal; Justine Liberato; Jinying Sun; Wendy Keitel; Jianhui Zhou
Journal:  Vaccine       Date:  2008-06-02       Impact factor: 3.641

9.  Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines.

Authors:  L Holten-Andersen; T M Doherty; K S Korsholm; P Andersen
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

10.  Molecular subtyping of Bacillus anthracis and the 2001 bioterrorism-associated anthrax outbreak, United States.

Authors:  Alex R Hoffmaster; Collette C Fitzgerald; Efrain Ribot; Leonard W Mayer; Tanja Popovic
Journal:  Emerg Infect Dis       Date:  2002-10       Impact factor: 6.883
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.